Thioether prodrug compositions as anti-hiv and anti-retroviral agents
AssigneesHealth and Human Services, The United States of America, as represented by the Secretary, Department of
InventorsDaniel Appella, Ettore Appella, John K. Inman, Lisa M. Miller Jenkins, Ryo Hayashi, Deyun Wang
Life of this patent
Estimating the term…
Abstract
Disclosed are inhibitors of retroviral growth of formula (I), that are useful in treatment of retroviral infections such as HIV. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, a method for inactivating a virus, a method for dissociating a metal ion from a zinc finger-containing protein, and a method for inhibiting the transmission of a virus.
Claims35
A compound of formula (I):
- wherein A, B, D, and E are each independently selected from CH, N, CR5, CR6, CR7, and CR8, with the proviso that not more than two of A, B, D, and E are N,
- R5, R6, R7, and R8 are independently selected from halogen, CF3, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, NO2, optionally substituted alkylthio, optionally substituted amino, optionally substituted acylamino, optionally substituted arylamino, optionally substituted acylthio, optionally substituted acyl, optionally substituted acyloxy, hydroxy, mercapto, and optionally substituted thioamido, or any of R5 and R6 taken together, R6 and R7 taken together, or R7 and R8 taken together form a 5- or 6-membered saturated or unsaturated ring,
- L1 is a bond or NR13,
- L2 is selected from H, optionally substituted alkyl, and NR1R2,
- J is selected from deuterium, J1, J2, J3, and J4,
- wherein J4 is aryl-R19 or heteroaryl-R20,
- wherein X is selected from O, S, and NR4,
- Y is selected from C(O)R3, C(S)R3, C(NR4)R3, and P(O)(OR14)2,
- R3 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylalkyl, optionally substituted cycloalkyl, and optionally substituted cycloalkylalkyl,
- R4 is selected from H, optionally substituted alkyl, optionally substituted aryl, and optionally substituted acyl,
- R14 is selected from H, optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted cycloalkyl, and optionally substituted cycloalkylalkyl, or, taken together, form a 5- or 6-membered ring,
- F, G, H, and I are each independently selected from CH, N, CR9, CR10, CR11, and CR12, with the proviso that not more than two of F, G, H, and I are N,
- R9, R10, and R12 are independently selected from halogen, CF3, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, NO2, optionally substituted alkylthio, optionally substituted amino, optionally substituted acylamino, optionally substituted arylamino, optionally substituted acylthio, optionally substituted acyl, optionally substituted acyloxy, hydroxy, mercapto, and optionally substituted thioamido, or any of R9 and R10 taken together, R10 and R11 taken together, or R11 and R12 taken together form a 5- or 6-membered saturated or unsaturated ring,
- R13 is selected from hydrogen, optionally substituted amino, optionally substituted acyl, optionally substituted aminoacyl, optionally substituted acyloxy, optionally substituted alkoxyacyl, optionally substituted aryloxyacyl, optionally substituted thioamido, hydroxy, optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted cycloalkyl, and optionally substituted cycloalkylalkyl,
- R15, R16, R17, and R18 are independently selected from H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl,
- R19 and R20 are selected from halogen, CF3, and NO2,
- Q is selected from a bond, optionally substituted alkylene, optionally substituted alkylene-C(O), optionally substituted phenylene, optionally substituted phenylene-C(O), optionally substituted cycloalkylene, optionally substituted cycloalkylene-C(O), optionally substituted alkyl cycloalkylene, optionally substituted alkylcycloalkylene-C(O), optionally substituted cycloalkylenealkyl, and optionally substituted cycloalkylenealkyl-C(O),
- R1 is selected from H, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroalkyl, and optionally substituted heterocycloalkyl, and
- R2 is selected from H, hydroxyl, amino, optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted alkylamine, optionally substituted arylamine, optionally substituted alkoxy, optionally substituted acyl, optionally substituted aminoacyl, optionally substituted alkoxyacyl, optionally substituted alkylthioacyl, optionally substituted arylaminoacyl, optionally substituted aryloxyacyl, optionally substituted arylthioacyl, optionally substituted heteroaryl, optionally substituted heteroalkyl, optionally substituted heterocycloalkyl and optionally substituted acylamino, or, alternatively,
- R1 and R2 are optionally linked together to form an optionally substituted ring of up to about seven atoms including the N to which both are attached,
- or a pharmaceutically acceptable salt thereof,
- with the proviso that when L1 is NR13 and Q is alkylene, L2 is not hydrogen.
-4. (canceled)
-7. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-33. (canceled)
(canceled)
-39. (canceled)
-45. (canceled)
(canceled)
-51. (canceled)
-66. (canceled)
-85. (canceled)
Dependencies are inferred from the claim text.